FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180428437> ?p ?o ?g. }

• W3180428437 endingPage "940" @default.
• W3180428437 startingPage "929" @default.
• W3180428437 abstract "Ropeginterferon alfa-2b (P1101) is a novel long-acting mono-PEGylated recombinant proline interferon (IFN) conjugated to a 40 kDa branched polyethylene glycol (PEG) chain at its N-terminus, allowing every-two-week injection. It received European Medicines Agency and Taiwan marketing authorization for the treatment of polycythemia vera in 2019 and 2020, respectively. This phase 2 study aimed to evaluate the pharmacokinetics, safety, and preliminary efficacy of ropeginterferon alfa-2b as compared with PEG-IFN-α2a in patients with chronic hepatitis C virus genotype 1 infection.One hundred six treatment naive patients were enrolled in this phase 2 study and randomized to four treatment groups: subcutaneous weekly PEG-IFN-α2a 180 μg (group 1), weekly ropeginterferon alfa-2b 180 μg (group 2), weekly ropeginterferon alfa-2b 270 μg (group 3), or biweekly ropeginterferon alfa-2b 450 μg (group 4) plus ribavirin for 48 weeks.After multiple weekly administration, serum exposure (AUC0-τ) in ropeginterferon alfa-2b 180 μg was approximately 41% greater and the accumulation ratio of 2-fold greater than PEG-IFN-α2a 180 μg. The incidences of flu-like symptoms were 66.7% (18/27), 53.3% (16/30), 55.0% (11/20), and 48.3% (14/29), anxiety were 14.8% (4/27), 6.7% (2/30), 0%, and 0%, and depression were 25.9% (7/27), 13.3% (4/30), 0%, and 3.4% (1/29), for groups 1-4, respectively. Two grade 2 of 3 depression were noted in PEG-IFN-α2a arm, but none in ropeginterferon arms. The SVR24 rates were 77.8% (21/27), 66.7% (20/30), 80% (16/20), and 69% (20/29), respectively.Ropeginterferon alfa-2b showed longer effective half-life and superior safety profile than PEG-IFN-α2a. Biweekly injection of ropeginterferon alfa-2b will be studied in larger viral hepatitis patient population." @default.
• W3180428437 created "2021-07-19" @default.
• W3180428437 creator A5004584429 @default.
• W3180428437 creator A5009330208 @default.
• W3180428437 creator A5009666113 @default.
• W3180428437 creator A5016525715 @default.
• W3180428437 creator A5040077466 @default.
• W3180428437 creator A5042155617 @default.
• W3180428437 creator A5054666319 @default.
• W3180428437 creator A5058253583 @default.
• W3180428437 creator A5058703698 @default.
• W3180428437 creator A5064282719 @default.
• W3180428437 creator A5074777324 @default.
• W3180428437 creator A5084164189 @default.
• W3180428437 creator A5085614261 @default.
• W3180428437 creator A5089634278 @default.
• W3180428437 creator A5091389432 @default.
• W3180428437 date "2021-07-10" @default.
• W3180428437 modified "2023-10-18" @default.
• W3180428437 title "Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy" @default.
• W3180428437 cites W1591804607 @default.
• W3180428437 cites W2008291489 @default.
• W3180428437 cites W2026329262 @default.
• W3180428437 cites W2027545702 @default.
• W3180428437 cites W2038448030 @default.
• W3180428437 cites W2042063943 @default.
• W3180428437 cites W2065614359 @default.
• W3180428437 cites W2071993332 @default.
• W3180428437 cites W2075282196 @default.
• W3180428437 cites W2080180136 @default.
• W3180428437 cites W2080437966 @default.
• W3180428437 cites W2086388926 @default.
• W3180428437 cites W2127685726 @default.
• W3180428437 cites W2139252405 @default.
• W3180428437 cites W2147596827 @default.
• W3180428437 cites W2150875695 @default.
• W3180428437 cites W2325408065 @default.
• W3180428437 cites W2348133702 @default.
• W3180428437 cites W2419462920 @default.
• W3180428437 cites W2503874329 @default.
• W3180428437 cites W2591155166 @default.
• W3180428437 cites W2900873801 @default.
• W3180428437 cites W2915431936 @default.
• W3180428437 cites W2968677045 @default.
• W3180428437 cites W2972422263 @default.
• W3180428437 cites W3003423609 @default.
• W3180428437 cites W3086711508 @default.
• W3180428437 cites W3092836453 @default.
• W3180428437 cites W3093730329 @default.
• W3180428437 cites W3129716601 @default.
• W3180428437 cites W3158785288 @default.
• W3180428437 cites W4211014289 @default.
• W3180428437 cites W4234500488 @default.
• W3180428437 doi "https://doi.org/10.1002/jgh3.12613" @default.
• W3180428437 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8341194" @default.
• W3180428437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34386602" @default.
• W3180428437 hasPublicationYear "2021" @default.
• W3180428437 type Work @default.
• W3180428437 sameAs 3180428437 @default.
• W3180428437 citedByCount "12" @default.
• W3180428437 countsByYear W31804284372021 @default.
• W3180428437 countsByYear W31804284372022 @default.
• W3180428437 countsByYear W31804284372023 @default.
• W3180428437 crossrefType "journal-article" @default.
• W3180428437 hasAuthorship W3180428437A5004584429 @default.
• W3180428437 hasAuthorship W3180428437A5009330208 @default.
• W3180428437 hasAuthorship W3180428437A5009666113 @default.
• W3180428437 hasAuthorship W3180428437A5016525715 @default.
• W3180428437 hasAuthorship W3180428437A5040077466 @default.
• W3180428437 hasAuthorship W3180428437A5042155617 @default.
• W3180428437 hasAuthorship W3180428437A5054666319 @default.
• W3180428437 hasAuthorship W3180428437A5058253583 @default.
• W3180428437 hasAuthorship W3180428437A5058703698 @default.
• W3180428437 hasAuthorship W3180428437A5064282719 @default.
• W3180428437 hasAuthorship W3180428437A5074777324 @default.
• W3180428437 hasAuthorship W3180428437A5084164189 @default.
• W3180428437 hasAuthorship W3180428437A5085614261 @default.
• W3180428437 hasAuthorship W3180428437A5089634278 @default.
• W3180428437 hasAuthorship W3180428437A5091389432 @default.
• W3180428437 hasBestOaLocation W31804284372 @default.
• W3180428437 hasConcept C10138342 @default.
• W3180428437 hasConcept C112705442 @default.
• W3180428437 hasConcept C126322002 @default.
• W3180428437 hasConcept C139719470 @default.
• W3180428437 hasConcept C162324750 @default.
• W3180428437 hasConcept C203014093 @default.
• W3180428437 hasConcept C2522874641 @default.
• W3180428437 hasConcept C2776178377 @default.
• W3180428437 hasConcept C2776235749 @default.
• W3180428437 hasConcept C2776461080 @default.
• W3180428437 hasConcept C2776867660 @default.
• W3180428437 hasConcept C2780040827 @default.
• W3180428437 hasConcept C2781228144 @default.
• W3180428437 hasConcept C2909179924 @default.
• W3180428437 hasConcept C3020491458 @default.
• W3180428437 hasConcept C54400483 @default.
• W3180428437 hasConcept C71924100 @default.
• W3180428437 hasConcept C90924648 @default.

• next